OBJECTIVES: Identification and review of used methods to derive patient utilities for health economic modelling in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) METHODS: A literature search of Embase, MEDLINE from 1996-2015 was conducted to identify health economic, clinical studies that hold information about deriving utilities in PsA, AS. Additionally HTA submissions in PsA, AS were also screened. Publication inclusion was limited to in English language, biological therapy in PsA or AS. RESULTS: In total the search retrieved 3,175 articles, of which 124 fulfilled screening criteria.  Most of the publications were screened for AS (n=73), followed by PsA (n=46) while five publications included both indications. Across studies baseline characteristics varied in age (Years, PsA: 35.5–65.0; AS: 24.4–61.0), disease duration (Years, AS: 0.7–30.2; PsA: 1.7–22.2) and gender distribution (Females, AS: 0–70%, PsA: 25–88%). No study was identified that used direct methods like time trade-off or standard gamble for utility derivation. Among generic measures SF-36 (n=27 for PsA, n=55 for AS), EQ-5D (n=10 PsA, n=14 AS) were primarily used. In total 45 different disease specific tools were identified (PsA, n=30; AS, n=15). The HAQ-DI (n=36) and ASQoL (n=21) were the most common tools in PsA, AS respectively. Among the cost-effectiveness studies 13 utility derivation algorithms in PsA and 5 in AS were identified. EQ-5D was the most commonly used HRQoL instrument to derive utilities (PsA, n=9; AS, n=3). Most cost-effectiveness models used HAQ-DI in PsA while BASFI, BASDAI were used in AS to derive utilities. CONCLUSIONS: Even though more publications were identified in AS, more utility derivation algorithms were identified in PsA. However no standard process has been established yet. Taking into consideration the variety of HRQoL tools and data available, more options could be explored to identify the most sensitive utility approach.